Biocon to launch psoriasis drug in July this year

29 Apr 2013 Evaluate

Biocon, Asia's premier biotechnology company, plans to launch its novel biologic drug Itolizumab branded as ‘Alzumab’ to be used for the treatment of chronic plaque psoriasis in the country. The biotechnology major is planning to launch it in month of July this year. The drug will be manufactured at the company’s biopharma manufacturing facility at Biocon Park in Bangalore.

In January 2013, the company received marketing authorization for Itolizumab from the Drugs Controller General of India. The company has also completed a pre-IND (Investigational New Drug) meeting for Itolizumab with the US Food and Drug Administration as it plans for a global clinical development of the new medicine. This is company’s second novel biologic developed in India. BioMab EGFR, an anti-cancer monoclonal antibody being the first.

Psoriasis is an inflammatory auto-immune skin disease that follows a typical relapsing and remitting course with the disease affecting 2-3% of the total population in the country. The global market for psoriasis treatments is estimated to cross $8 billion by 2016.

Biocon is India’s premier biotechnology company with a strategic focus on biopharmaceuticals and research services. Biocon produces anti-diabetic agents like Acarbose, Pioglitazone, Repaglinides and Rosiglitazone. In the biological segment it produces Insulin, Erythropoietin (EPO), Filgrastim (GCSF), Streptokinase and Monoclonal Antibodies.

Biocon Share Price

392.80 4.55 (1.17%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×